Moffitt Cancer Center | Strategic Alliance Partners

October 05, 2021

Rachid Baz, MD, discusses the role of alkylating agents in relapsed/refractory multiple myeloma.

October 01, 2021

Bijal Shah, MD, MS, discusses the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

October 01, 2021

Brandon Blue, MD, discusses the utility of carfilzomib in relapsed/refractory multiple myeloma.

September 30, 2021

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.

September 30, 2021

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

September 29, 2021

Rachid Baz, MD, discusses the utility of venetoclax in patients with heavily pretreated multiple myeloma.

September 28, 2021

Rohit Jain, MD, MPH, discusses the nuances of treatment selection for patients with platinum-eligible vs -ineligible metastatic urothelial carcinoma, the current state of immunotherapy in this disease, and factors to consider during the decision-making process in RCC and mCRPC.

September 28, 2021

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

September 14, 2021

Ricardo Costa, MD, MSc, discusses the patient population included in the phase 3 OlympiA trial in breast cancer.

August 31, 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses the potential for immunotherapy in ovarian cancer.

August 30, 2021

Jingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.

August 30, 2021

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

August 19, 2021

Nivolumab followed by treatment with tumor-infiltrating lymphocytes was generally safe and found to have clinical benefit in patients with metastatic non–small cell lung cancer.

August 16, 2021

Martine Extermann, MD, PhD, shares advice for selecting among the CDK4/6 available for the treatment of patients with hormone receptor–positive breast cancer.

August 16, 2021

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

August 16, 2021

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer. 

August 13, 2021

Due to the potency of CAR T-cell therapies and the associated adverse events that can to arise in patients receiving this type of treatment, oncology nurses need to be educated on how to best identify and manage these AEs.

August 12, 2021

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

August 12, 2021

The widening treatment paradigm for various breast cancer subtypes is yielding improved survival with more tailored strategies.

August 11, 2021

Martine Extermann, MD, PhD, discusses the utility of single-agent trastuzumab in HER2-positive breast cancer.